Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hidden danger: study probes blood clot risk in cancer patients with COVID-19

NCT ID NCT04616846

Knowledge-focused Sponsor: Centre Antoine Lacassagne Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study investigates how often cancer patients with COVID-19 develop dangerous blood clots (venous thromboembolism). Researchers will screen participants using ultrasound and blood tests to detect clots, whether or not they cause symptoms. The goal is to understand the true rate of clotting in this vulnerable group and help guide future prevention and treatment strategies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors identify which cancer patients with COVID-19 are at highest risk for dangerous blood clots, leading to better screening and prevention guidelines.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test any new therapy. The findings may not apply to all cancer patients or all COVID-19 variants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

88 people

The number who actually took part.

Started

Aug 2020

Finished

Jan 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * COVID-19 testing ; * Age ≥ 18 years old ; * Patient treated for histologically proven cancer (under treatment or last anti-neoplastic treatment \< 3 months at the time of COVID-19 testing); * For the infected cohort: patient being screened for VTE at least one time 7 weeks after the COVID-19 diagnosistwo time point (day 1-10 after COVID-19 testing, and day 20-25 after COVID-19 testing) for retrospective cohort only; * Complete blood count available at time of COVID-19 testing (+/-14 days) to be able to calculate the Khorana score; * Patient informed and not opposed to the data processing; * Patient affiliated with a health insurance system. Exclusion Criteria: * Patient not able to give free consent; * Patient not able to understand the protocol; * For the infected patients: VTE screening not performed (for retrospective cohort only); * No available complete blood count at time of COVID-19 testing; Medical file and clinical follow-up not available during the study period (76 weeks after the COVID-19 test); * Patients under 18 years; * Vulnerable persons as defined by article L1121-5-8: 1. Pregnant women, women in labour or breast-feeding mothers, persons deprived of their freedom by judicial or administrative decision, persons hospitalized without their consent by virtue of articles L. 3212-1 and L. 3213-1 and who are not subject to the provisions of article L. 1121-8 2. Persons admitted to a social or health facility for reasons other than research 3. Adults subject to a legal protection order or unable to give their consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer COVID-19 neoplasm Thromboembolism venous thromboembolism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID19 Neoplasms, malignant Thromboembolism

Contacts and locations

Locations

  • CHPG

    Monaco, 98000, Monaco

  • CHU Nice

    Nice, Alpes-Maritimes, 06000, France

  • Centre Antoine Lacassagne

    Nice, Alpes-Maritimes, 06189, France

  • Centre Azuréen de Cancérologie

    Mougins, Alpes-Maritimes, 06250, France

  • Clinique Saint-Georges

    Nice, Alpes-Maritimes, 06105, France

  • Clinique Saint-Jean

    Cagnes-sur-Mer, Alpes-Maritimes, 06800, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.